Guiping Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guiping Yu has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Kun Yan
Department of Cardiothoracic Surgery, Jiangyin Clinical College of Xuzhou Medical University
6 shared publicationsBin Huang
Department of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu Province 214400, China
5 shared publicationsPraise Audax Rukonge
Department of Cardiothoracic Surgery The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu China
4 shared publicationsYedong Mi
Department of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu Province 214400, China
4 shared publicationsZhimeng Lu
Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University
4 shared publicationsYifan Sheng
Wuxi Key Laboratory of Biomaterials for Clinical Application, Department of Central Laboratory, Jiangyin Clinical College of Xuzhou Medical University
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4) , e70435
Integrated Network Pharmacology and Experimental Validation Implicate AKT1‐Associated Signaling in the Protective Effects of Panax notoginseng Against Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive and fatal cardiopulmonary disease characterized by pulmonary vascular remodeling, endothelial dysfunction, inflammation, and increased pulmonary vascular resistance. Despite advances in targeted therapies, effective treatment options remain limited. This study investigated the molecular mechanisms underlying the therapeutic effects of Panax notoginseng against PAH through integrated computational and experimental validation. Network pharmacology was employed to identify the bioactive compounds and therapeutic targets of Panax notoginseng . Functional enrichment, protein–protein interaction network analysis, transcriptomic validation, molecular docking, surface plasmon resonance (SPR), molecular dynamics simulation, and MM/PBSA analyses were performed to characterize representative target–compound interactions. Experimental validation to predict the therapeutic mechanism was performed using RAW264.7 macrophages, pulmonary artery smooth muscle cells (PASMCs), and a Sugen5416/hypoxia‐induced murine model of PAH. A total of 67 overlapping therapeutic targets were identified, with enrichment analyses highlighting inflammation, oxidative stress, apoptosis, vascular remodeling, and the PI3K/AKT signaling pathway. AKT1 was identified as a central hub gene and was significantly upregulated under hypoxic conditions. Quercetin and Liquiritigenin (DFV)exhibited stable interactions with AKT1, with quercetin demonstrating stronger binding affinity (−11.10 kcal/mol) than liquiritigenin (−9.33 kcal/mol). Consistent with these computational predictions, Panax notoginseng reduced AKT1 expression and phosphorylation, attenuated oxidative stress and inflammatory cytokine production, inhibited PASMC proliferation and migration, and significantly improved pulmonary hemodynamics, right ventricular hypertrophy, and pulmonary vascular remodeling in vivo. Collectively, these findings identify AKT1 as a key molecular target through which Panax notoginseng exerts therapeutic effects against PAH in vivo.
- 29 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4) , e70435
Open AccessIntegrated Network Pharmacology and Experimental Validation Implicate AKT1‐Associated Signaling in the Protective Effects of Panax notoginseng Against Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive and fatal cardiopulmonary disease characterized by pulmonary vascular remodeling, endothelial dysfunction, inflammation, and increased pulmonary vascular resistance. Despite advances in targeted therapies, effective treatment options remain limited. This study investigated the molecular mechanisms underlying the therapeutic effects of Panax notoginseng against PAH through integrated computational and experimental validation. Network pharmacology was employed to identify the bioactive compounds and therapeutic targets of Panax notoginseng . Functional enrichment, protein–protein interaction network analysis, transcriptomic validation, molecular docking, surface plasmon resonance (SPR), molecular dynamics simulation, and MM/PBSA analyses were performed to characterize representative target–compound interactions. Experimental validation to predict the therapeutic mechanism was performed using RAW264.7 macrophages, pulmonary artery smooth muscle cells (PASMCs), and a Sugen5416/hypoxia‐induced murine model of PAH. A total of 67 overlapping therapeutic targets were identified, with enrichment analyses highlighting inflammation, oxidative stress, apoptosis, vascular remodeling, and the PI3K/AKT signaling pathway. AKT1 was identified as a central hub gene and was significantly upregulated under hypoxic conditions. Quercetin and Liquiritigenin (DFV)exhibited stable interactions with AKT1, with quercetin demonstrating stronger binding affinity (−11.10 kcal/mol) than liquiritigenin (−9.33 kcal/mol). Consistent with these computational predictions, Panax notoginseng reduced AKT1 expression and phosphorylation, attenuated oxidative stress and inflammatory cytokine production, inhibited PASMC proliferation and migration, and significantly improved pulmonary hemodynamics, right ventricular hypertrophy, and pulmonary vascular remodeling in vivo. Collectively, these findings identify AKT1 as a key molecular target through which Panax notoginseng exerts therapeutic effects against PAH in vivo.
- Open Access
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1889276
From granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis
Although antibiotic therapy effectively cures active tuberculosis (TB), many survivors are left with permanent lung damage and long-lasting immune alterations. Growing epidemiological evidence indicates that individuals with prior pulmonary TB have a two- to three-fold increased risk of lung cancer, independent of smoking, suggesting mechanisms beyond shared risk factors. This review advances the concept that TB imprints a durable “memory” within the lung, characterized by persistent structural remodeling and immune reprogramming that together create a tumor-permissive microenvironment. We synthesize evidence showing that TB granulomas act as dynamic immune niches that induce hypoxia, fibrosis, and immune exhaustion, features that frequently persist after microbiological cure. Post-TB sequelae including fibrotic scarring, cavitation, bronchiectasis, and vascular remodeling, promote chronic inflammation, oxidative DNA damage, and mechanotransduction pathways linked to oncogenesis. Concurrently, sustained T-cell exhaustion, macrophage polarization toward tumor-associated phenotypes, and impaired antigen presentation weaken tumor surveillance. We further discuss emerging roles for lung microbiome dysbiosis in sustaining inflammation. Collectively, these processes provide a mechanistic framework linking healed TB to lung carcinogenesis and highlight TB survivors as a distinct population for targeted surveillance and preventive strategies.
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1889276
Open AccessFrom granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis
Although antibiotic therapy effectively cures active tuberculosis (TB), many survivors are left with permanent lung damage and long-lasting immune alterations. Growing epidemiological evidence indicates that individuals with prior pulmonary TB have a two- to three-fold increased risk of lung cancer, independent of smoking, suggesting mechanisms beyond shared risk factors. This review advances the concept that TB imprints a durable “memory” within the lung, characterized by persistent structural remodeling and immune reprogramming that together create a tumor-permissive microenvironment. We synthesize evidence showing that TB granulomas act as dynamic immune niches that induce hypoxia, fibrosis, and immune exhaustion, features that frequently persist after microbiological cure. Post-TB sequelae including fibrotic scarring, cavitation, bronchiectasis, and vascular remodeling, promote chronic inflammation, oxidative DNA damage, and mechanotransduction pathways linked to oncogenesis. Concurrently, sustained T-cell exhaustion, macrophage polarization toward tumor-associated phenotypes, and impaired antigen presentation weaken tumor surveillance. We further discuss emerging roles for lung microbiome dysbiosis in sustaining inflammation. Collectively, these processes provide a mechanistic framework linking healed TB to lung carcinogenesis and highlight TB survivors as a distinct population for targeted surveillance and preventive strategies.
- 14 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (22) , 7052-7065
Trimetallic nano trap-mediated glycolytic and mitochondrial metabolism co-inhibition: ATP suppression for enhanced metal ion-interference therapy
Mitochondria serve as central regulators of tumorigenesis, progression, metastasis, and chemoresistance, playing a pivotal role in cancer bioenergetics and thus representing prime targets for anticancer therapy.
- 14 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (22) , 7052-7065
Trimetallic nano trap-mediated glycolytic and mitochondrial metabolism co-inhibition: ATP suppression for enhanced metal ion-interference therapy
Mitochondria serve as central regulators of tumorigenesis, progression, metastasis, and chemoresistance, playing a pivotal role in cancer bioenergetics and thus representing prime targets for anticancer therapy.
- 12 February 2026
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 505, 141459
Exposomic analysis of emerging contaminants associated with lung cancer risk and recurrence using pseudo-targeted LC–MS/MS
- 12 February 2026
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 505, 141459
Exposomic analysis of emerging contaminants associated with lung cancer risk and recurrence using pseudo-targeted LC–MS/MS
- Open Access
- 14 November 2025
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 51 (1) , 339
Comparative study of total thoracoscopic and traditional incision internal fixation for the treatment of multiple rib fractures
Objective: To investigate the clinical efficacy of total thoracoscopic memory alloy embracing fixator(MAEF) internal fixation surgery for multiple rib fractures. Methods: A retrospective analysis was conducted on the clinical data of 83 patients with multiple rib fractures who underwent surgical treatment in our department from September 2020 to February 2025. The patients were divided into an observation group (total thoracoscopic group, n = 40) and a control group (traditional incision group, n = 43) according to the surgical method. The clinical data of the two groups were compared. Results: The operative time in the observation group was longer. However, after stratification according to the learning curve, it was found that the operative time in the observation group showed no significant difference compared with the control group after the surgical technique became proficient ( P > 0.05). The pain index and partial pressure of oxygen one day before surgery, intraoperative blood loss, postoperative pleural drainage volume, and fracture healing status in the observation group showed no significant differences compared with the control group ( P > 0.05). Pain scores and oxygen partial pressures on postoperative days 3 and 5 were significantly better in the observation group than in the control group( P < 0.05). The postoperative hospital stay duration was significantly shorter in the observation group than in the control group ( P < 0.05). Conclusion: The total thoracoscopic MAEF internal fixation surgery for multiple rib fractures is easy to learn, causes minimal trauma, and allows for a rapid postoperative recovery. The fracture healing achieved is comparable to that of open thoracotomy surgery.
- 14 November 2025
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 51 (1) , 339
Open AccessComparative study of total thoracoscopic and traditional incision internal fixation for the treatment of multiple rib fractures
Objective: To investigate the clinical efficacy of total thoracoscopic memory alloy embracing fixator(MAEF) internal fixation surgery for multiple rib fractures. Methods: A retrospective analysis was conducted on the clinical data of 83 patients with multiple rib fractures who underwent surgical treatment in our department from September 2020 to February 2025. The patients were divided into an observation group (total thoracoscopic group, n = 40) and a control group (traditional incision group, n = 43) according to the surgical method. The clinical data of the two groups were compared. Results: The operative time in the observation group was longer. However, after stratification according to the learning curve, it was found that the operative time in the observation group showed no significant difference compared with the control group after the surgical technique became proficient ( P > 0.05). The pain index and partial pressure of oxygen one day before surgery, intraoperative blood loss, postoperative pleural drainage volume, and fracture healing status in the observation group showed no significant differences compared with the control group ( P > 0.05). Pain scores and oxygen partial pressures on postoperative days 3 and 5 were significantly better in the observation group than in the control group( P < 0.05). The postoperative hospital stay duration was significantly shorter in the observation group than in the control group ( P < 0.05). Conclusion: The total thoracoscopic MAEF internal fixation surgery for multiple rib fractures is easy to learn, causes minimal trauma, and allows for a rapid postoperative recovery. The fracture healing achieved is comparable to that of open thoracotomy surgery.
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 6326-6338
Narrative review of the application of artificial intelligence-related technologies in the diagnosis of pulmonary nodules with recommendations for clinical practice and future research
Background and Objective: Lung cancer has the highest global incidence and mortality rate among malignancies, primarily due to the complexity and diversity of early lung nodules and tumor changes, in addition to the involvement of numerous other factors, such as delayed screening for early lung nodules and difficulties in treatment. With the continuous optimization of artificial intelligence (AI) models, novel paradigms are emerging in the detection of malignant pulmonary nodules, histopathologic subtyping, and genomic prediction—advances that increasingly inform clinical assessment and therapeutic decision-making. This article reviews Chinese and English research over the past 10 years and explores the current application status of AI in the diagnosis of pulmonary nodules. Methods: Literature available primarily from the PubMed, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases was collected and analyzed to characterize the current state of AI application in the diagnosis of pulmonary nodules across different disciplines. The following keywords were used in the search: “lung cancer”, “ground-glass nodules (GGN)”, “artificial intelligence”, “deep learning”, “machine learning”, “radiomics”, “pathology of lung cancer”, and “genomics”. The search is limited to English and Chinese publications within the last 10 years, with no restrictions on the age or country of the participants. Key Content and Findings: This study reviews the application of AI in pulmonary nodule diagnosis across imaging, pathology, and genetics. Recently, AI technology has found extensive applications in the healthcare sector. AI significantly enhances the accuracy of early diagnosis and the efficiency of individualized decision-making. However, the standardization of models is insufficient, external validation is scarce, and large-scale prospective studies are still needed to support clinical applications. Conclusions: AI is expected to play a significant role in the diagnosis, radiomics, pathology and genomics of pulmonary nodules in the future. Existing evidence can support the differentiation between benign and malignant pulmonary nodules, improve diagnostic efficiency, and predict pathological types and gene mutations. Thus, AI has a promising application prospect in clinical practice.
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 6326-6338
Open AccessNarrative review of the application of artificial intelligence-related technologies in the diagnosis of pulmonary nodules with recommendations for clinical practice and future research
Background and Objective: Lung cancer has the highest global incidence and mortality rate among malignancies, primarily due to the complexity and diversity of early lung nodules and tumor changes, in addition to the involvement of numerous other factors, such as delayed screening for early lung nodules and difficulties in treatment. With the continuous optimization of artificial intelligence (AI) models, novel paradigms are emerging in the detection of malignant pulmonary nodules, histopathologic subtyping, and genomic prediction—advances that increasingly inform clinical assessment and therapeutic decision-making. This article reviews Chinese and English research over the past 10 years and explores the current application status of AI in the diagnosis of pulmonary nodules. Methods: Literature available primarily from the PubMed, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases was collected and analyzed to characterize the current state of AI application in the diagnosis of pulmonary nodules across different disciplines. The following keywords were used in the search: “lung cancer”, “ground-glass nodules (GGN)”, “artificial intelligence”, “deep learning”, “machine learning”, “radiomics”, “pathology of lung cancer”, and “genomics”. The search is limited to English and Chinese publications within the last 10 years, with no restrictions on the age or country of the participants. Key Content and Findings: This study reviews the application of AI in pulmonary nodule diagnosis across imaging, pathology, and genetics. Recently, AI technology has found extensive applications in the healthcare sector. AI significantly enhances the accuracy of early diagnosis and the efficiency of individualized decision-making. However, the standardization of models is insufficient, external validation is scarce, and large-scale prospective studies are still needed to support clinical applications. Conclusions: AI is expected to play a significant role in the diagnosis, radiomics, pathology and genomics of pulmonary nodules in the future. Existing evidence can support the differentiation between benign and malignant pulmonary nodules, improve diagnostic efficiency, and predict pathological types and gene mutations. Thus, AI has a promising application prospect in clinical practice.
- 7 April 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 210, 104716
Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy
- 7 April 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 210, 104716
Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy
- Open Access
- 22 January 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (1) , 27047
SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis
Background: This study investigates the role of small ubiquitin-like modifier (SUMO)-specific peptidase 5 (SENP5), a key regulator of SUMOylation, in esophageal squamous cell carcinoma (ESCC), a lethal disease, and its underlying molecular mechanisms. Methods: Differentially expressed genes between ESCC mouse oesophageal cancer tissues and normal tissues were analysed via RNA-seq; among them, SENP5 expression was upregulated, and this gene was selected for further analysis. Immunohistochemistry and western blotting were then used to validate the increased protein level of SENP5 in both mouse and human ESCC samples. The Kaplan‒Meier method and multivariate analysis were used to analyse the relationship between SENP5 expression and ESCC prognosis. Stable SENP5-knockdown (KD) cell lines and conditional knockout (cKO) mice were established to verify the biological function of SENP5. Further RNA-seq comparisons between short hairpin SENP5 (shSENP5)- and short hairpin negative control (shNC)-transfected ESCC cell lines were conducted, and the nuclear factor kappa B (NF-κB)—SLC1A3 axis was identified through bioinformatics analysis. The correlation of SENP5 with signalling pathway components was validated via real-time quantitative PCR (qPCR), western blotting (WB), and immunoprecipitation. Results: Our study revealed that SENP5 was upregulated in human and mouse ESCC samples, and clinical data analysis revealed a correlation between high SENP5 expression and poor patient prognosis. SENP5 knockdown inhibited tumorigenesis and growth in vivo and suppressed the proliferation, migration, and invasion of ESCC cell lines in vitro. Our study also revealed that SENP5 knockdown enhanced the SUMO1-mediated SUMOylation of NF-kappa-B inhibitor alpha (IκBα), thereby inhibiting the activation of the NF-κB–SLC1A3 axis, which subsequently suppresses ESCC cell energy metabolism and impedes ESCC progression. Conclusions: Suppression of SENP5 slows the development of ESCC by inhibiting the NF-κB‒SLC1A3 axis through SUMO1-mediated SUMOylation of IκBα. Our research suggests that SENP5 could serve as a prognostic indicator and a target for therapeutic intervention for ESCC patients.
- 22 January 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (1) , 27047
Open AccessSUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis
Background: This study investigates the role of small ubiquitin-like modifier (SUMO)-specific peptidase 5 (SENP5), a key regulator of SUMOylation, in esophageal squamous cell carcinoma (ESCC), a lethal disease, and its underlying molecular mechanisms. Methods: Differentially expressed genes between ESCC mouse oesophageal cancer tissues and normal tissues were analysed via RNA-seq; among them, SENP5 expression was upregulated, and this gene was selected for further analysis. Immunohistochemistry and western blotting were then used to validate the increased protein level of SENP5 in both mouse and human ESCC samples. The Kaplan‒Meier method and multivariate analysis were used to analyse the relationship between SENP5 expression and ESCC prognosis. Stable SENP5-knockdown (KD) cell lines and conditional knockout (cKO) mice were established to verify the biological function of SENP5. Further RNA-seq comparisons between short hairpin SENP5 (shSENP5)- and short hairpin negative control (shNC)-transfected ESCC cell lines were conducted, and the nuclear factor kappa B (NF-κB)—SLC1A3 axis was identified through bioinformatics analysis. The correlation of SENP5 with signalling pathway components was validated via real-time quantitative PCR (qPCR), western blotting (WB), and immunoprecipitation. Results: Our study revealed that SENP5 was upregulated in human and mouse ESCC samples, and clinical data analysis revealed a correlation between high SENP5 expression and poor patient prognosis. SENP5 knockdown inhibited tumorigenesis and growth in vivo and suppressed the proliferation, migration, and invasion of ESCC cell lines in vitro. Our study also revealed that SENP5 knockdown enhanced the SUMO1-mediated SUMOylation of NF-kappa-B inhibitor alpha (IκBα), thereby inhibiting the activation of the NF-κB–SLC1A3 axis, which subsequently suppresses ESCC cell energy metabolism and impedes ESCC progression. Conclusions: Suppression of SENP5 slows the development of ESCC by inhibiting the NF-κB‒SLC1A3 axis through SUMO1-mediated SUMOylation of IκBα. Our research suggests that SENP5 could serve as a prognostic indicator and a target for therapeutic intervention for ESCC patients.
- Open Access
- 8 January 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-19
Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas
Recent advancements in contemporary therapeutic approaches have increased the survival rates of lung cancer patients; however, the long-term benefits remain constrained, underscoring the pressing need for novel biomarkers. Surfactant-associated 3 (SFTA3), a long non-coding RNA predominantly expressed in normal lung epithelial cells, plays a crucial role in lung development. Nevertheless, its function in lung adenocarcinoma (LUAD) remains inadequately understood. Single-cell RNA sequencing data were utilized to identify novel cancer cell-intrinsic gene signatures associated with the progression of LUAD, and their roles in LUAD were comprehensively analyzed. Serum samples were collected to quantify the expression levels of SFTA3 in LUAD patients. Furthermore, a series of biological experiments, including cell viability assays, scratch wound healing assays, and colony formation assays, were conducted to demonstrate the tumor-suppressive effects of SFTA3. RNA sequencing was performed to elucidate the molecular mechanisms underlying the role of SFTA3 in lung cancer cells. We constructed a prognostic model comprising eight genes: ALDOA, ATP5MD, SERPINH1, SFTA3, SLK, U2SURP, SCGB1A1, and SCGB1A3. The model effectively stratified patients into high- and low-risk categories, revealing that low-risk patients experienced superior clinical outcomes, exhibited an immunologically hot tumor microenvironment (TME), and had a greater probability of responding to immunotherapy. In contrast, the high-risk group exhibited a cold TME and may benefit more from chemotherapy. Furthermore, our study revealed that a progressive decrease in SFTA3 expression in cancer cells was correlated with tumor advancement. Notably, the serum levels of SFTA3 significantly decreased in patients with LUAD, suggesting its potential utility in liquid biopsy for LUAD diagnosis. Additionally, the knockdown of SFTA3 enhances the proliferation and migration of lung cancer cells, whereas its overexpression inhibits these phenotypes. The epithelial-mesenchymal transition pathway was significantly enriched following SFTA3 silencing, suggesting that SFTA3 may impact tumor progression by modulating this process. We also identified key transcription factors and epigenetic mechanisms implicated in the downregulation of SFTA3 in LUAD. We developed a robust prognostic model and identified SFTA3 as a novel biomarker with potential applications in the diagnosis, prognosis, and personalized treatment of LUAD. Additionally, our findings offer new insights into the mechanisms underlying LUAD tumorigenesis and immune evasion.
- 8 January 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-19
Open AccessIdentification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas
Recent advancements in contemporary therapeutic approaches have increased the survival rates of lung cancer patients; however, the long-term benefits remain constrained, underscoring the pressing need for novel biomarkers. Surfactant-associated 3 (SFTA3), a long non-coding RNA predominantly expressed in normal lung epithelial cells, plays a crucial role in lung development. Nevertheless, its function in lung adenocarcinoma (LUAD) remains inadequately understood. Single-cell RNA sequencing data were utilized to identify novel cancer cell-intrinsic gene signatures associated with the progression of LUAD, and their roles in LUAD were comprehensively analyzed. Serum samples were collected to quantify the expression levels of SFTA3 in LUAD patients. Furthermore, a series of biological experiments, including cell viability assays, scratch wound healing assays, and colony formation assays, were conducted to demonstrate the tumor-suppressive effects of SFTA3. RNA sequencing was performed to elucidate the molecular mechanisms underlying the role of SFTA3 in lung cancer cells. We constructed a prognostic model comprising eight genes: ALDOA, ATP5MD, SERPINH1, SFTA3, SLK, U2SURP, SCGB1A1, and SCGB1A3. The model effectively stratified patients into high- and low-risk categories, revealing that low-risk patients experienced superior clinical outcomes, exhibited an immunologically hot tumor microenvironment (TME), and had a greater probability of responding to immunotherapy. In contrast, the high-risk group exhibited a cold TME and may benefit more from chemotherapy. Furthermore, our study revealed that a progressive decrease in SFTA3 expression in cancer cells was correlated with tumor advancement. Notably, the serum levels of SFTA3 significantly decreased in patients with LUAD, suggesting its potential utility in liquid biopsy for LUAD diagnosis. Additionally, the knockdown of SFTA3 enhances the proliferation and migration of lung cancer cells, whereas its overexpression inhibits these phenotypes. The epithelial-mesenchymal transition pathway was significantly enriched following SFTA3 silencing, suggesting that SFTA3 may impact tumor progression by modulating this process. We also identified key transcription factors and epigenetic mechanisms implicated in the downregulation of SFTA3 in LUAD. We developed a robust prognostic model and identified SFTA3 as a novel biomarker with potential applications in the diagnosis, prognosis, and personalized treatment of LUAD. Additionally, our findings offer new insights into the mechanisms underlying LUAD tumorigenesis and immune evasion.